Please assess the completion status of the following clinical trial:

Trial Title: Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with liver biopsy fibrosis score stage 4 (NASH CRN) performed within 12 months~* Men and women must agree to follow methods of contraception~Exclusion Criteria:~* Worsening liver disease or any disease might compromise participant safety in the opinion of the investigator~* Known immunocompromised status or any disease or condition which might compromise participant safety~* Prior exposure to BMS-986263~* Clinically relevant abnormal physical examination, vital signs, ECG, or clinical laboratory tests~* Hepatic decompensation~Other protocol-defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Dose A BMS-986263 (Type: EXPERIMENTAL): None
- Dose B BMS-986263 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).